Which GLP-1 drug will have the highest US market share by revenue on December 1, 2025?
4
125Ṁ140resolved Dec 2
100%4%
Zepbound
83%
Ozempic
4%
Wegovy
4%
Mounjaro
4%Other
This question is managed and resolved by Manifold.
Get 
1,000 to start trading!
1,000🏅 Top traders
| # | Name | Total profit |
|---|---|---|
| 1 | Ṁ5 |
Sort by:
Resolved:
People are also trading
Related questions
Will a drug company pay >$1m in a class action suit based on their statements about their GLP1 inhibitor by 2026?
38% chance
Ozempic will NOT be the leading GLP-1 agonist by total $ US sales by December 31, 2025
42% chance
Will one of the GLP agonist drugs (eg Semaglutude/Wegovy Tirzepatide/Mounjaro) have a black box warning by 2025
7% chance
Will an oral insulin pill be publicly available before the end of 2025?
12% chance
Will a GLP-1 agonist diabetes / weight loss drug be the top bestselling drug in 2025?
30% chance
Will either Lada Nuzhan or Jose Luis Ricon give in and inject semaglutide/tirzepatide at least 3 times before EOY 2025?
43% chance
Will a majority government owned company introduce a new GLP-1 drug before 2040?
15% chance
Will Retatrutide (new obesity drug) be FDA approved by the end of 2025?
5% chance
Will GLP-1 agonists help stop or reverse the US obesity trend by end of 2027
84% chance
What fraction of US adults will regularly take GLP-1 drugs in 2030?